The present study examines the mechanism of renal clearance of two maj
or warfarin metabolites, S-7-hydroxywarfarin and R,S-warfarin alcohol,
in three healthy subjects who each received 1.5 mg/kg rac-warfarin al
one (control) or in combination with phenylbutazone (PBZ). The unbound
fraction of warfarin metabolites (fu(m)) was predicted using the unbo
und fraction of warfarin enantiomers determined, using equilibrium dia
lysis at 37 degrees C and an enantioselective HPLC assay. In the contr
ol phase the unbound renal clearance (CLuR) ranged from 182 to 583 ml/
min (mean, 318) for S-7-hydroxywarfarin and from 23 to 191 ml/min (mea
n, 96) for R,S-warfarin alcohol. For S-7-hydroxywarfarin CLuR was much
greater than the glomerular filtration rate (GFR) indicating that thi
s metabolite undergoes net secretion in the kidney. In two subjects CL
uR for R,S-warfarin alcohol was less than GFR indicating that this met
abolite undergoes net tubular reabsorption. The CLuR in each subject f
or both metabolites was notably lower during the coadministration of P
BZ (39 to 62 ml/min for S-7-hydroxywarfarin and 5 to 17 ml/min for R,S
-warfarin alcohol) suggesting that this drug inhibits renal secretion
of these metabolites. The inhibition of renal secretion of metabolites
by PBZ allows an estimation of the minimum fraction of filtered metab
olite that undergoes reabsorption, being 86% to 90% for R,S-warfarin a
lcohol and 51% to 69% for S-7-hydroxywarfarin. The difference is proba
bly explained by the greater polarity of S-7-hydroxywarfarin. Analysis
also indicates that under control conditions secretion is a major com
ponent of renal excretion for both metabolites, accounting for 80% and
84% of metabolite entering the renal tubules for S-7-hydroxywarfarin
and R,S-warfarin alcohol, respectively.